【ChiCTR2300079249】The determination of the comparative effect of ertugliflozin, pioglitazone, and metformin in patients of nonalcoholic fatty liver diseases in type 2 diabetes mellitus.
ChiCTR2300079249
正在进行
/
/
/
2023-12-28
/
/
Non-Alcoholic fatty liver diseases with type 2 diabetes mellitus
The determination of the comparative effect of ertugliflozin, pioglitazone, and metformin in patients of nonalcoholic fatty liver diseases in type 2 diabetes mellitus.
The determination of the comparative effect of ertugliflozin, pioglitazone, and metformin in patients of nonalcoholic fatty liver diseases in type 2 diabetes mellitus.
The aim and objective of this study is to evaluate the effect of ertugliflozin on Non alcoholic fatty liver diseases patients with type 2 diabetes mellitus along with its impact on the function of liver enzymes. The purpose of the study is to determine the effect of ertugliflozin, pioglitazone, and metformin in the improvement of nonalcoholic fatty liver diseases with type 2 diabetes mellitus. Other outcomes include improvement in an elevated liver enzyme and blood cholesterol as well as a change in the quality of life of the patient.
随机平行对照
探索性研究/预试验
Computer generated randomization. The participants will be randomized into three groups. The random technique will be used form a list of random numbers obtained from computer of eligible patients which will be compiled by using the patients’ hospital identification numbers.
Blinded (masking used). The study is double blinded nether the participant know and nether the experimenter or investigator knows.
自筹
/
60
/
2024-01-01
2024-08-31
/
Participants for this randomize control trail must be Adult patients with age above 20 years and less than 70 years diagnosed with non alcoholic fatty liver diseases along with type 2 diabetes mellitus.；
请登录查看Participants not having non alcoholic fatty liver diseases along with type 2 diabetes mellitus, not willing to participate and the patient having elevated liver enzyme with any other risk factor such as hepatitis or other viral infection.；
请登录查看ADIL KHALIQ
/
ADIL KHALIQ的其他临床试验
DEPARTMENT OF PHARMACY ABDUL WALI KHAN UNIVERSITY MARDAN KYBERPAKHTUNKHWA PAKISTAN的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04